Severe hypertension and rapidly progressive acute renal failure is a well recognized complication of scleroderma, often referred to as the renal crisis, and widely thought to cause irreversible deterioration in renal function. With the advent of angiotensin-converting-enzyme inhibitors (ACE-I) the outlook for patients with this condition has dramatically improved. We report here one such patient.
CASE HISTORY
A 43-year old West Indian woman presented with a 12 month history of incomplete Raynaud's phenomenon, 5 months of progressive swelling and stiffness of her hands, forearms, feet and legs; and tightness of the skin around her throat. There was no relevant past medical history, but she smoked 30 cigarettes a day. She had had to give up her job as a typist due to stiffness in her hands.
On examination there was tight waxy skin over her forearms, hands, feet, legs, upper chest and throat, compatible with scleroderma. There was no rash or synovitis. Her resting blood pressure was 160/120 mmHg. Examination was otherwise unremarkable, and a diagnosis of scleroderma was made.
The following day she was admitted with pericarditic chest pains. Investigations revealed evidence of microangiopathic haemolytic anaemia with fragmented red blood cells, Hb 8.4 g/dl, reticulocytes 10%; thrombocytopenia (platelets 79x 10 911), and renal failure (urea 9.3mmolll; creat.211 I!molll, rising to 365 I!molll within 24h). Renal ultrasound was normal: urinalysis was normal except for proteinurea of 0.5 g/24 h. Echocardiogram revealed an enlarged heart with a pericardial effusion but no tamponade. Her blood pressure had risen to 200/125, and nifedipine (20mg b.d.) was commenced. Due to poor response, this was changed to captopril (increasing to 25mg t.d.s.) 36h after admission, which produced satisfactory control. Despite this rapidly progressive renal failure developed, and a subsequent renal biopsy showed changes compatible with scleroderma ( Figure  1 ). Seven days after admission she was commenced on continuous ambulatory peritoneal dialysis (CAPO), by which time her serum creatinine was 1073 I!molli.
Further investigations revealed disordered oesophageal motility but no evidence of lung disease.
After seven months, during which she maintained a small urine output, her renal function was found to be stable without CAPO (urea 18.3mmolll, creat.391 umol/I) and dialysis was discontinued.
After 3 years she remains well, with occasional retrosternal chest pain and breathlessness, sclerodermatous skin changes, and stable renal function (creat.177I!moIlI). Her blood pressure is well controlled on enalapril and frusemide.
DISCUSSION
Scleroderma renal cnsis is characterized by systemic hypertension, marked elevation of plasma renin, and rapid deterioration in renal function (often associated with microangiopathic haemolytic anaemia and thrombocytopenia), in patients with systemic sclerosis having diffuse skin involvement. This occurs in about 10-45% of sufferers, usually within 4 years of the presentation1.2. A role for systemic glucocorticosteroids in precipitating this condition has been suggested. Most cases occur in the absence of preceeding steroid therapv", however, in the small percentage of patients who develop acute renal failure in the absence of severe hypertension increased antecedent use of steroids is observed/, and doubt still exists.
In a retrospective analysis, Traub has reported mortality of 100% within one year of renal crisis" in patients presenting before 1971. With dialysis and more effective antihypertensive agents, but before the introduction of ACE-I, l-year mortality fell to 85%5.
The observation that plasma renin levels are elevated in renal crisis'' led to the use of ACE-I at the onset of renal failure. Conflicting reports on the efficacy of ACE-I in improving renal function are found in the literature of the early 1980' s, with some workers showing a beneficial response 7 ,8, and others finding progressive irreversible renal failure 9 , 10 despite normalization of blood pressure.
In 1990 Steen et 01. reviewed their survival figures in patients treated with and without ACE-Is, and showed that without ACE-I 40 of 53 (75%) patients were dead within six months. Of the remainder nine were on long term dialysis, only four having a good outcome. In contrast only 15 of the 55 (27%) patients treated with ACE-I died, and of the 20 who required dialysis 11 were able to discontinue within 15 months. Predictors of a poor outcome were male sex, increasing age, poor left ventricular function and a serum creatinine greater than 270 Jlmolll (3.0 mg/ dl) at presentation. Although other factors, such as improved dialysis techniques and a more aggressive approach, may have improved outcome in the ACE-I, this study provides support for the beneficial effects of these agents. Helfrich/ has noted four out of five normotensive patients who developed renal failure also had significantly elevated renin levels, and although numbers reported are small, ACE-I may be of benefit here also.
In our patient captopril was commenced within 48 h of first presentation, and we feel that this contributed to her favourable outcome.
This case and the review of the literature suggests that all hypertensive patients with scleroderma, with or without renal failure, should be treated with an ACE-I as a first line agent. With aggressive management of blood pressure and renal failure in this manner, the outlook is potentially good, and long term dialysis may be avoided.
